CA2932353A1 - Methods to treat lymphoplasmacytic lymphoma - Google Patents
Methods to treat lymphoplasmacytic lymphoma Download PDFInfo
- Publication number
- CA2932353A1 CA2932353A1 CA2932353A CA2932353A CA2932353A1 CA 2932353 A1 CA2932353 A1 CA 2932353A1 CA 2932353 A CA2932353 A CA 2932353A CA 2932353 A CA2932353 A CA 2932353A CA 2932353 A1 CA2932353 A1 CA 2932353A1
- Authority
- CA
- Canada
- Prior art keywords
- certain embodiments
- optionally substituted
- group
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915684P | 2013-12-13 | 2013-12-13 | |
| US61/915,684 | 2013-12-13 | ||
| US201462036917P | 2014-08-13 | 2014-08-13 | |
| US62/036,917 | 2014-08-13 | ||
| PCT/US2014/070167 WO2015089481A2 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2932353A1 true CA2932353A1 (en) | 2015-06-18 |
Family
ID=53371973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2932353A Pending CA2932353A1 (en) | 2013-12-13 | 2014-12-12 | Methods to treat lymphoplasmacytic lymphoma |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9908872B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3079682A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6878004B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014361800B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2932353A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015089481A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE50030E1 (en) | 2013-12-13 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| WO2015089481A2 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
| CA3010631A1 (en) | 2016-01-13 | 2017-07-20 | Stora Enso Oyj | Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof |
| WO2017147700A1 (en) | 2016-03-01 | 2017-09-08 | Ontario Institute For Cancer Research (Oicr) | Inhibitors of wdr5 protein-protein binding |
| JP2019507179A (ja) | 2016-03-01 | 2019-03-14 | プロペロン セラピューティックス インコーポレイテッド | Ｗｄｒ５タンパク質−タンパク質結合の阻害剤 |
| AU2017363313B2 (en) * | 2016-11-22 | 2021-06-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| EP3548479A1 (en) * | 2016-11-30 | 2019-10-09 | ARIAD Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
| JP7167069B2 (ja) * | 2017-06-29 | 2022-11-08 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害剤ならびに作製および使用のための方法 |
| CA3090275A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| CN108707147A (zh) * | 2018-06-20 | 2018-10-26 | 桑文军 | 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| ES2979163T3 (es) | 2018-10-31 | 2024-09-24 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| WO2023183377A1 (en) | 2022-03-23 | 2023-09-28 | Rigel Pharmaceuticals, Inc. | Pyrimid-2-yl-pyrazole compounds as irak inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9816837D0 (en) * | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| JP2002512216A (ja) | 1998-04-17 | 2002-04-23 | パーカー ヒューズ インスティテュート | Ｂｔｋインヒビターならびにその同定方法および使用方法 |
| KR20010099609A (ko) * | 1998-08-04 | 2001-11-09 | 다비드 에 질레스 | 사이토킨의 생성 억제제로서 유용한 아미드 유도체 |
| IL141979A0 (en) * | 1998-09-25 | 2002-03-10 | Astrazeneca Ab | Benzamide derivatives and their use as cytokine inhibitors |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
| PL375447A1 (en) | 2002-08-14 | 2005-11-28 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| JP4896518B2 (ja) * | 2002-12-13 | 2012-03-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | ニコチンアミド系キナーゼ阻害薬 |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| AU2005317870A1 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
| WO2006067445A2 (en) * | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| CN101106990B (zh) | 2005-01-26 | 2010-12-08 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| AU2006278627B2 (en) | 2005-08-08 | 2011-08-18 | Janssen Pharmaceutica, N.V. | Thiazolopyrimidine kinase inhibitors |
| US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| US8101610B2 (en) * | 2005-11-14 | 2012-01-24 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
| WO2007076474A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| US20090312396A1 (en) | 2006-07-10 | 2009-12-17 | Astrazeneca Ab | Methods for cancer treatment using tak1 inhibitors |
| ES2616789T3 (es) * | 2006-09-22 | 2017-06-14 | Pharmacyclics, Inc. | Inhibidores de tirosina cinasa de Bruton |
| WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| TW200906825A (en) | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| WO2009017822A2 (en) | 2007-08-02 | 2009-02-05 | Amgen Inc. | Pi3 kinase modulators and methods of use |
| US8067423B2 (en) | 2007-10-23 | 2011-11-29 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof |
| WO2009076373A1 (en) | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| JP5529852B2 (ja) | 2008-05-06 | 2014-06-25 | ジリード コネティカット，インコーポレイティド | 置換アミド、その製造法及びＢｔｋインヒビターとしての使用 |
| BRPI0918021B1 (pt) * | 2008-08-13 | 2023-03-14 | Mitsui Chemicals Agro, Inc | Derivados de amida, agente de controle de peste contendo os derivados de amida, e método de controle de pragas |
| MX2011001989A (es) | 2008-09-02 | 2011-03-30 | Boehringer Ingelheim Int | Nuevas benzamidas, su preparacion y su uso como medicamentos. |
| US8598174B2 (en) | 2008-11-12 | 2013-12-03 | Genetech, Inc. | Pyridazinones, method of making, and method of use thereof |
| US8809534B2 (en) | 2009-09-03 | 2014-08-19 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| WO2011029043A1 (en) | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| MX358682B (es) | 2010-07-13 | 2018-08-31 | Hoffmann La Roche | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
| WO2012062704A1 (en) | 2010-11-09 | 2012-05-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| EP2640366A2 (en) | 2010-11-15 | 2013-09-25 | Exelixis, Inc. | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture |
| BR112013029640A2 (pt) * | 2011-05-23 | 2017-06-13 | Merck Patent Gmbh | derivados de piridina e pirazina |
| US9073947B2 (en) * | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| PH12014500738A1 (en) * | 2011-10-03 | 2014-05-12 | Syngenta Participations Ag | Insecticidal 2-methoxybenzamide derivatives |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| EP2773639B1 (en) | 2011-11-03 | 2017-04-26 | F. Hoffmann-La Roche AG | Alkylated piperazine compounds as inhibitors of btk activity |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| AU2012354094C1 (en) | 2011-12-15 | 2015-10-15 | Novartis Ag | Use of inhibitors of the activity or function of PI3K |
| CN103405429A (zh) * | 2013-08-22 | 2013-11-27 | 中国药科大学 | 一类vegfr-2抑制剂及其用途 |
| WO2015069287A1 (en) | 2013-11-08 | 2015-05-14 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| WO2015089481A2 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| USRE50030E1 (en) | 2013-12-13 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
-
2014
- 2014-12-12 WO PCT/US2014/070167 patent/WO2015089481A2/en not_active Ceased
- 2014-12-12 AU AU2014361800A patent/AU2014361800B2/en not_active Ceased
- 2014-12-12 EP EP14869351.8A patent/EP3079682A4/en active Pending
- 2014-12-12 US US15/104,005 patent/US9908872B2/en active Active
- 2014-12-12 CA CA2932353A patent/CA2932353A1/en active Pending
- 2014-12-12 JP JP2016539167A patent/JP6878004B2/ja active Active
-
2018
- 2018-02-23 US US15/904,143 patent/US10597387B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10597387B2 (en) | 2020-03-24 |
| EP3079682A2 (en) | 2016-10-19 |
| AU2014361800A1 (en) | 2016-06-09 |
| JP6878004B2 (ja) | 2021-05-26 |
| AU2014361800B2 (en) | 2020-05-07 |
| WO2015089481A2 (en) | 2015-06-18 |
| US20160311807A1 (en) | 2016-10-27 |
| WO2015089481A3 (en) | 2015-10-29 |
| EP3079682A4 (en) | 2017-08-30 |
| JP2017504595A (ja) | 2017-02-09 |
| US20180186780A1 (en) | 2018-07-05 |
| US9908872B2 (en) | 2018-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2932353A1 (en) | Methods to treat lymphoplasmacytic lymphoma | |
| CA2932351A1 (en) | Methods to treat lymphoplasmacytic lymphoma | |
| US12281118B2 (en) | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use | |
| CA3041563C (en) | Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12) | |
| JP6892444B2 (ja) | Ｍｎｋ１およびｍｎｋ２のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬 | |
| US10525060B2 (en) | HCK as a therapeutic target in MYD88 mutated diseases | |
| CA2965178C (en) | Thiazolyl-containing compounds for treating proliferative diseases | |
| JP6888006B2 (ja) | Ｍｎｋ１およびｍｎｋ２を阻害するピロロ−、ピラゾロ−、イミダゾ−ピリミジンおよびピリジン化合物 | |
| CA2955082A1 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
| CA3157331A1 (en) | A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases | |
| BR112014017735B1 (pt) | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto | |
| AU2017280293B2 (en) | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof | |
| WO2025011444A1 (zh) | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 | |
| WO2019180686A1 (en) | Ido-tdo dual inhibitor and related methods of use | |
| WO2025240238A1 (en) | Thieno[3,4-d]pyrimidin-4-amine inhibitors of hck |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191209 |
|
| EEER | Examination request |
Effective date: 20191209 |
|
| EEER | Examination request |
Effective date: 20191209 |
|
| EEER | Examination request |
Effective date: 20191209 |
|
| EEER | Examination request |
Effective date: 20191209 |
|
| EEER | Examination request |
Effective date: 20191209 |
|
| EEER | Examination request |
Effective date: 20191209 |
|
| EEER | Examination request |
Effective date: 20191209 |